TBR 220

Drug Profile

TBR 220

Alternative Names: TAK-220; TBR-220

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Takeda
  • Developer Tobira Therapeutics
  • Class Antiretrovirals; Piperidines; Small molecules
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 01 Nov 2016 Tobira Therapeutics has been acquired by Allergan
  • 20 Aug 2008 TBR 220 is still in phase I trials for the treatment of HIV-1 infections in Europe and US
  • 01 Aug 2007 TAK 220 licensed to Tobira Therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top